FibroBiologics, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.6M
- Price
- $1.44
- % Change (Daily % change from the live per-ticker quote feed.)
- +11.63%
- Volume
- 570.6K
About
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Quick stats
Shares outstanding6.7M
Computed float5.7M
Float / shares86.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001958777
AI Summary
AI-generated1/33
minorbullishclinical trial
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
FibroBiologics reported that its chondrocyte spheroids (FSdCS) demonstrated cartilage repair in animal models within four weeks of a single injection.
The preclinical study highlighted a four-day manufacturing process and potential for lower costs compared to other therapeutic approaches for degenerative joint disease.
Management characterized the results as proof of concept for a regenerative therapy that could eventually replace invasive surgical interventions.